(Q34537070)

2 August 2017

1 reference

title

Supportive and symptomatic management of amyotrophic lateral sclerosis (English)

1 reference

amyotrophic lateral sclerosis

2 August 2017

main subject

1 reference

Esther V Hobson

1

1 reference

2 August 2017

Christopher J McDermott

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

12 August 2016

1 reference

2 August 2017

published in

Nature Reviews Neurology

1 reference

2 August 2017

volume

12

1 reference

2 August 2017

issue

9

1 reference

2 August 2017

page(s)

526-538

1 reference

https://scigraph.springernature.com/pub.10.1038/nrneurol.2016.111

2 August 2017

exact match

0 references

cites work

Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study.

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A proposed staging system for amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Use of clinical staging in amyotrophic lateral sclerosis for phase 3 clinical trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Prognosis in amyotrophic lateral sclerosis: a population-based study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A controlled trial of riluzole in amyotrophic lateral sclerosis. ALS/Riluzole Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: drug, nutritional, and respiratory therapies (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the Am

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The natural history of motor neuron disease: assessing the impact of specialist care

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A multidisciplinary clinic approach improves survival in ALS: a comparative study of ALS in Ireland and Northern Ireland

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Multidisciplinary ALS care improves quality of life in patients with ALS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Multidisciplinary team working in motor neurone disease: patient and family carer views

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

What influences patient decision-making in amyotrophic lateral sclerosis multidisciplinary care? A study of patient perspectives

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Using technology to improve access to specialist care in amyotrophic lateral sclerosis: A systematic review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A randomized trial of mexiletine in ALS: Safety and effects on muscle cramps and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Spasticity: pathophysiology, evaluation and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The value of muscle exercise in patients with amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Intrathecal baclofen for intractable spasticity in amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Use of intrathecal baclofen for treatment of spasticity in amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Intrathecal baclofen for spasticity-related pain in amyotrophic lateral sclerosis: efficacy and factors associated with pain relief

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Pain in amyotrophic lateral sclerosis: a population-based controlled study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Medication in the last days of life for motor neuron disease/amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

End-of-life management in patients with amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Clinico-pathological features in amyotrophic lateral sclerosis with expansions in C9ORF72.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Frequency of the C9orf72 hexanucleotide repeat expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a cross-sectional study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A prospective cohort study of neuropsychological test performance in ALS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Executive dysfunction is a negative prognostic indicator in patients with ALS without dementia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Screening for cognition and behaviour changes in ALS.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

ALS-Plus syndrome: non-pyramidal features in a large ALS cohort.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Pathologic laughter and crying in ALS: a search for their origin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Treatment of pseudobulbar affect in ALS with dextromethorphan/quinidine: a randomized trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Pharmacologic Treatment of Emotional Lability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Depression and anxiety in individuals with amyotrophic lateral sclerosis: epidemiology and management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A longitudinal study on quality of life and depression in ALS patient-caregiver couples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Modafinil treatment of fatigue in patients with ALS: a placebo-controlled study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Communications Technology and Motor Neuron Disease: An Australian Survey of People With Motor Neuron Disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Head-Up; An interdisciplinary, participatory and co-design process informing the development of a novel head and neck support for people living with progressive neck muscle weakness.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Evaluating a novel cervical orthosis, the Sheffield Support Snood, in patients with amyotrophic lateral sclerosis/motor neuron disease with neck weakness

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Purposes of AAC device use for persons with ALS as reported by caregivers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

An eye-tracking assistive device improves the quality of life for ALS patients and reduces the caregivers' burden

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Towards personalized speech synthesis for augmentative and alternative communication.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Brain-computer interfaces in amyotrophic lateral sclerosis: A metanalysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A decrease in body mass index is associated with faster progression of motor symptoms and shorter survival in ALS

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Body mass index, not dyslipidemia, is an independent predictor of survival in amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Nutritional state, energy intakes and energy expenditure of amyotrophic lateral sclerosis (ALS) patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Hypermetabolism in ALS patients: an early and persistent phenomenon.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

High metabolic level in patients with familial amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Is There a Role for Exercise in the Management of Bulbar Dysfunction in Amyotrophic Lateral Sclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Impact of expiratory strength training in amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Autologous myoblasts attenuate atrophy and improve tongue force in a denervated tongue model: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

ALS dysphagia pathophysiology: differential botulinum toxin response

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Gastrostomy use in motor neurone disease (MND): a review, meta-analysis and survey of current practice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The impact of gastrostomy in motor neurone disease: challenges and benefits from a patient and carer perspective

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Gastrostomy in patients with amyotrophic lateral sclerosis (ProGas): a prospective cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Factors influencing decision-making in relation to timing of gastrostomy insertion in patients with motor neurone disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Eating-derived pleasure in amyotrophic lateral sclerosis as a predictor of non-oral feeding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Effects of non-invasive ventilation on survival and quality of life in patients with amyotrophic lateral sclerosis: a randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A study to evaluate safety and tolerability of repeated doses of tirasemtiv in patients with amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Early treatment with noninvasive positive pressure ventilation prolongs survival in Amyotrophic Lateral Sclerosis patients with nocturnal respiratory insufficiency.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Non-invasive ventilation in motor neuron disease: an update of current UK practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Nocturnal pulse oximetry: a new approach to establish the appropriate time for non‐invasive ventilation in ALS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Using transcutaneous carbon dioxide monitor (TOSCA 500) to detect respiratory failure in patients with amyotrophic lateral sclerosis: A validation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The initiation of non-invasive ventilation for patients with motor neuron disease: patient and carer perceptions of obstacles and outcomes.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The impact on the family carer of motor neurone disease and intervention with noninvasive ventilation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Prognostic value of efficiently correcting nocturnal desaturations after one month of non-invasive ventilation in amyotrophic lateral sclerosis: a retrospective monocentre observational cohort study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Identifying who will benefit from non-invasive ventilation in amyotrophic lateral sclerosis/motor neurone disease in a clinical cohort

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Management of sialorrhoea in motor neuron disease: a survey of current UK practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Randomized double-blind study of botulinum toxin type B for sialorrhea in ALS patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Long-term follow-up of ultrasound-guided botulinum toxin-A injections for sialorrhea in neurological dysphagia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Acute deterioration of bulbar function after botulinum toxin treatment for sialorrhoea in amyotrophic lateral sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Radiotherapy reduces sialorrhea in amyotrophic lateral sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Comparison of Radiotherapy Types in the Treatment of Sialorrhea in Amyotrophic Lateral Sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Peak flow and peak cough flow in the evaluation of expiratory muscle weakness and bulbar impairment in patients with neuromuscular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Predictors of ineffective cough during a chest infection in patients with stable amyotrophic lateral sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Prevention of pulmonary morbidity for patients with neuromuscular disease.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

A preliminary randomized trial of the mechanical insufflator-exsufflator versus breath-stacking technique in patients with amyotrophic lateral sclerosis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

High-frequency chest wall oscillation in ALS: an exploratory randomized, controlled trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Safety and efficacy of diaphragm pacing in patients with respiratory insufficiency due to amyotrophic lateral sclerosis (DiPALS): a multicentre, open-label, randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Experiences of dying, death and bereavement in motor neurone disease: a qualitative study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Motor Neurone Disease family carers' experiences of caring, palliative care and bereavement: an exploratory qualitative study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The use of non-invasive ventilation at end of life in patients with motor neurone disease: a qualitative exploration of family carer and health professional experiences

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Withdrawal of ventilation at the patient's request in MND: a retrospective exploration of the ethical and legal issues that have arisen for doctors in the UK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Home tracheotomy mechanical ventilation in patients with amyotrophic lateral sclerosis: causes, complications and 1-year survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Tracheostomy mechanical ventilation in patients with amyotrophic lateral sclerosis: clinical features and survival analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

ALS patients on TPPV: totally locked-in state, neurologic findings and ethical implications.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Carer quality of life and experiences of health services: a cross-sectional survey across three neurological conditions

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Predictors of psychological distress in carers of people with amyotrophic lateral sclerosis: a longitudinal study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The need for support services for family carers of people with motor neurone disease (MND): views of current and former family caregivers a qualitative study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Developing and evaluating complex interventions: the new Medical Research Council guidance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Non-invasive ventilation in motor neuron disease: current UK practice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Non-invasive ventilation in amyotrophic lateral sclerosis: a 10 year population based study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

The strange allure of state "right-to-try" laws

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Subjects no more: what happens when trial participants realize they hold the power?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Sharing health data for better outcomes on PatientsLikeMe

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Shared decision making: really putting patients at the centre of healthcare

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRNEUROL.2016.111

Early use of non invasive ventilation in patients with amyotrophic lateral sclerosis: what benefits?

31 March 2020

1 reference

12 December 2020

[The effect of amitriptyline on the pathological crying and other pseudobulbar signs].

1 reference

12 December 2020

EFNS guidelines on the clinical management of amyotrophic lateral sclerosis (MALS)--revised report of an EFNS task force

1 reference

12 December 2020

Is tracheostomy still an option in amyotrophic lateral sclerosis? Reflections of a multidisciplinary work group

1 reference

12 December 2020

Depression, pain and quality of life in patients with amyotrophic lateral sclerosis: a cross-sectional study

1 reference

12 December 2020

Treatment for spasticity in amyotrophic lateral sclerosis/motor neuron disease

1 reference

12 December 2020

Treatment for cramps in amyotrophic lateral sclerosis/motor neuron disease

1 reference

12 December 2020

Quinine for muscle cramps

1 reference

12 December 2020

Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease

1 reference

12 December 2020

10.1038/NRNEUROL.2016.111

Identifiers

DOI

1 reference

Dimensions Publication ID

2 August 2017

1028525572

0 references

1 reference